Atrial fibrillation pulmonary diseases: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 44: Line 44:


2. [[Beta blockers]], [[sotalol]], [[propafenone]], and [[adenosine]] are not recommended in patients with [[obstructive lung disease]] who develop [[AF]]. ''(Level of Evidence: C)''}}
2. [[Beta blockers]], [[sotalol]], [[propafenone]], and [[adenosine]] are not recommended in patients with [[obstructive lung disease]] who develop [[AF]]. ''(Level of Evidence: C)''}}
==See Also==
* [[The Living Guidelines: Diagnosis and Management of Atrial Fibrillation | The AF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]]


==Sources==
==Sources==

Revision as of 13:44, 17 June 2009

Conduction
Sinus rhythm
Atrial fibrillation
Atrihttp://miles.wikidoc.org/skins/common/images/button_bold.pngal fibrillation
The P waves, which represent depolarization of the atria, are irregular or absent during atrial fibrillation.
ICD-10 I48
ICD-9 427.31
DiseasesDB 1065
MedlinePlus 000184
eMedicine med/184  emerg/46

WikiDoc Resources for Atrial fibrillation pulmonary diseases

Articles

Most recent articles on Atrial fibrillation pulmonary diseases

Most cited articles on Atrial fibrillation pulmonary diseases

Review articles on Atrial fibrillation pulmonary diseases

Articles on Atrial fibrillation pulmonary diseases in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Atrial fibrillation pulmonary diseases

Images of Atrial fibrillation pulmonary diseases

Photos of Atrial fibrillation pulmonary diseases

Podcasts & MP3s on Atrial fibrillation pulmonary diseases

Videos on Atrial fibrillation pulmonary diseases

Evidence Based Medicine

Cochrane Collaboration on Atrial fibrillation pulmonary diseases

Bandolier on Atrial fibrillation pulmonary diseases

TRIP on Atrial fibrillation pulmonary diseases

Clinical Trials

Ongoing Trials on Atrial fibrillation pulmonary diseases at Clinical Trials.gov

Trial results on Atrial fibrillation pulmonary diseases

Clinical Trials on Atrial fibrillation pulmonary diseases at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Atrial fibrillation pulmonary diseases

NICE Guidance on Atrial fibrillation pulmonary diseases

NHS PRODIGY Guidance

FDA on Atrial fibrillation pulmonary diseases

CDC on Atrial fibrillation pulmonary diseases

Books

Books on Atrial fibrillation pulmonary diseases

News

Atrial fibrillation pulmonary diseases in the news

Be alerted to news on Atrial fibrillation pulmonary diseases

News trends on Atrial fibrillation pulmonary diseases

Commentary

Blogs on Atrial fibrillation pulmonary diseases

Definitions

Definitions of Atrial fibrillation pulmonary diseases

Patient Resources / Community

Patient resources on Atrial fibrillation pulmonary diseases

Discussion groups on Atrial fibrillation pulmonary diseases

Patient Handouts on Atrial fibrillation pulmonary diseases

Directions to Hospitals Treating Atrial fibrillation pulmonary diseases

Risk calculators and risk factors for Atrial fibrillation pulmonary diseases

Healthcare Provider Resources

Symptoms of Atrial fibrillation pulmonary diseases

Causes & Risk Factors for Atrial fibrillation pulmonary diseases

Diagnostic studies for Atrial fibrillation pulmonary diseases

Treatment of Atrial fibrillation pulmonary diseases

Continuing Medical Education (CME)

CME Programs on Atrial fibrillation pulmonary diseases

International

Atrial fibrillation pulmonary diseases en Espanol

Atrial fibrillation pulmonary diseases en Francais

Business

Atrial fibrillation pulmonary diseases in the Marketplace

Patents on Atrial fibrillation pulmonary diseases

Experimental / Informatics

List of terms related to Atrial fibrillation pulmonary diseases

Cardiology Network

Discuss Atrial fibrillation pulmonary diseases further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Synonyms and related keywords: AF, Afib, fib

Overview

ACC / AHA Guidelines- Pulmonary Diseases (DO NOT EDIT) [1]

Class I

1. Correction of hypoxemia and acidosis is the recommended primary therapeutic measure for patients who develop AF during an acute pulmonary illness or exacerbation of chronic pulmonary disease. (Level of Evidence: C)

2. A non dihydropyridine calcium channel antagonist (diltiazem or verapamil) is recommended to control the ventricular rate in patients with obstructive pulmonary disease who develop AF. (Level of Evidence: C)

3. Direct-current cardioversion should be attempted in patients with pulmonary disease who become hemodynamically unstable as a consequence of AF. (Level of Evidence: C)

Class III

1. Theophylline and beta-adrenergic agonist agents are not recommended in patients with bronchospastic lung disease who develop AF. (Level of Evidence: C)

2. Beta blockers, sotalol, propafenone, and adenosine are not recommended in patients with obstructive lung disease who develop AF. (Level of Evidence: C)

See Also

Sources

  • The ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation [1]

References

  1. 1.0 1.1 Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation- Executive Summary: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidlines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: 700-752. PMID 16908781

Further Readings

  • Fuster V, Rydén LE, Cannom DS, et al (2006). "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation 114 (7): e257-354. doi:10.1161/CIRCULATIONAHA.106.177292. PMID 16908781.
  • Estes NAM 3rd, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie JL, Romeo SJW, Waldo AL, Wyse DG. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with non valvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Performance Measures for Atrial Fibrillation). Circulation 2008; 117:1101–1120

Template:SIB

de:Vorhofflimmern it:Fibrillazione atriale nl:Boezemfibrilleren no:Atrieflimmer fi:Eteisvärinä


Template:WikiDoc Sources